A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma
Completed · Phase 1
Conditions studied: Metastatic Melanoma
In brief
To evaluate the safety of intratumorally injected VCL-IM01 at doses of 0.5 mg (1 tumor), 1.5 mg (1 tumor), 5 mg (1 tumor), 10 mg (2 tumors, 5 mg per tumor) and 15 mg (3 tumors, 5 mg per tumor) followed by electroporation.
Key facts
- Study ID
- NCT00223899
- Run by
- Vical
- People needed
- 26
- Starts
- 2005-07-01
- Expected to finish
- 2008-10-01
- Last updated by the study team
- 2019-02-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Location #2 — Mobile, Alabama, United States
- Location #3 — Denver, Colorado, United States
- Location #1 — Chicago, Illinois, United States
- Location #4 — Montclair, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.